
An FDA advisory panel has voted against backing Novartis’ Ilaris for gouty arthritis because of safety concerns. Ilaris (canakinumab) is …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

